A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Morse, Michael A ^a   Garst, Jennifer ^a   Osada, Takuya ^a   Khan, Shubi ^a   Hobeika, Amy ^a   Clay, Timothy M ^a   Valente, Nancy ^b,c   Shreeniwas, Revati ^b   Sutton, Mary Ann ^b   Delcayre, Alain ^b   Hsu, Di Hwei ^b   Le Pecq, Jean Bernard ^b   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Anosys Inc   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; HLA A2 ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 3DPO4; MELANOMA ANTIGEN 4; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; INJECTION SITE REACTION; LEUKAPHERESIS; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MALE; NATURAL KILLER CELL; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; SKIN INDURATION; T LYMPHOCYTE; VACCINE PRODUCTION;

EID: 18144369346     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-9     Document Type: Article

References (30)

1. Gotoh K, Yatabe Y, Sugiura T, Takagi K, Ogawa M, Takahashi T, Takahashi T, Mitsudomi T: Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer 1998, 20:117-125.
2. Shichijo S, Hayashi A, Takamori S, Tsunosue R, Hoshino T, Sakata M, Kuramoto T, Oizumi K, Itoh K: Detection of MAGE-4 protein in lung cancers. Int J Cancer 1995, 64:158-65.
3. Park JW, Kwon TK, Kim IH, Sohn SS, Kim YS, Kim CI, Bae OS, Lee KS, Lee KD, Lee CS, Chang HK, Choe BK, Ahn SY, Jeon CH: A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods 2002, 266:79-86.
4. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC: Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003, 9:657-662.
5. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998, 4:594-600.
6. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183:1161-1172.
7. Martinez-Lorenzo MJ, Anel A, Gamen S, Monle n I, Lasierra P, Larrad L, Pineiro A, Alava MA, Naval J: human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol 1999, 163:1274-1281.
8. Skokos D, Le Panse S, Villa I, Rousselle JC, Peronet R, David B, Namane A, Mecheri S: Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol 2001, 166:868-876.
9. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ: Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999, 94:3791-3799.
10. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001, 7:297-303.
11. Farsad K: Exosomes: novel organelles implicated in immunomodulation and apoptosis. Yale J Biol Med 2002, 75:95-101.
12. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000, 113: 3365-3374.
13. Schartz NE, Chaput N, Andre F, Zitvogel L: From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. Curr Opin Mol Ther 2002, 4:372-381.
14. Johnstone RM: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem Cell Biol 1992, 70:179-190.
15. Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C, Geuze HJ: Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 2000, 165: 1259-1265.
16. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L: Malignant effusions and immunogenic tumor derived-exosomes. Lancet 2002, 360: 295-305.
17. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002, 3:1156-1162.
18. Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB: Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother 2003, 26:440-450.
19. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S: Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001, 166:7309-7318.
20. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999, 147:599-610.
21. Thery C, Zitvogel L, Amigorena S: Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2002, 2:569-579.
22. André F, Chaput N, Schartz NEC, et al.: Exosomes as potent cellfree peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC ClassI/peptide complexes to dendritic cells. J Immunol 2004, 172:2126-2136.
23. Lamparski H, Metha-Damani A, Yao J, Patel S, Hsu D, Ruegg C, Le Pecq J: Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002, 270:211.
24. + cytolytic T lymphocytes. Cancer Res 2000, 60:6272-6275.
25. Whiteside TL: Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol Invest 2000, 29:149-162.
26. Garcia-Lora A, Algarra I, Garrido F: MHC class I antigens, immune surveillance and tumor immune escape. J Cell Physiol 2003, 195:346-351.
27. Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
28. Fossella FV, DeVore R, Kerr RN, et al.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
29. Massarelli E, Andre F, Liu DD, et al.: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003, 39:55-61.
30. Pfister DG, Johnson DH, Azzoli CG, et al.: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.